Average Insider

Where insiders trade, we follow

$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$27.80
Current Price
$19.67B
Market Cap
52W Low$8.73
Current$27.8088.3% above low, 11.7% below high
52W High$30.33

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells22$6,848,573.48241,861
1 monthBuys00--All Sells
Sells22$6,848,573.48241,861
2 monthsBuys00--All Sells
Sells722$201,146,591.637,458,654
3 monthsBuys00--All Sells
Sells725$234,433,092.108,989,522
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Feb 13, 2026
QVT Financial LP
Director by Deputization
Sale150,784$26.49$3,994,268.16View Details
Feb 9, 2026
Sukhatme Mayukh
Director
Sale339,441$26.47$8,985,003.27View Details
Jan 12, 2026
Venker Eric
President & Immunovant CEO
Sale200,000$21.92$4,384,000.00View Details
Dec 31, 2025
Sukhatme Mayukh
Director
Sale1,018,995$21.71$22,122,381.45View Details
Dec 29, 2025
Sukhatme Mayukh
Director
Sale311,873$21.74$6,780,119.02View Details
72 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
May 27, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Feb 9, 2026
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
Feb 6, 2026
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.3.33